First Medical Marijuana Clinical Trial Registered With Health Canada – Yahoo Finance

It will also explore the short-term safety of vapourized cannabis as well as to look at functional changes and patient preference. Prairie Plant Systems is currently finalizing the agreements with the two main trial sites. Patient recruitment details will be announced in the coming weeks. “With 36 per cent of the patients registered in the former MMAR program suffering with symptoms of serve arthritis – the largest concentration of any disease area – we felt there was no option but to continue our clinical exploration within this important patient group,” said Brent Zettl, President and CEO of Prairie Plant Systems and CanniMed. “Today we are announcing the launch of our clinical trial program where we will formally study several varieties of medical marijuana to determine not only the safety and efficacy of pharmaceutical-grade cannabis, but also to provide prescribing physicians with the clinical data they are looking for regarding dosing.” Studies show that the body’s own pain-regulating system, (the endocannabinoid system) has receptors in nervous system tissue, immune cells, bone and joint tissue. These receptors respond to the cannabinoids found in medical marijuana, similar to how a key opens a lock. Medical marijuana research has demonstrated its efficacy at reducing pain when used by itself or in combination with other pain-relievers. Many cases of anecdotal evidence have been reported for arthritis patients who have very successfully used medical marijuana either in conjunction with traditional therapy or alone. “Well designed controlled trials are needed to answer many of the claims made around medical cannabis,” says Dr. Mark Ware, executive director of the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and a practicing pain physician at the McGill University Health Centre.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/first-medical-marijuana-clinical-trial-130000981.html